Table 2

Rates of severe hypoglycemic events by year for adult participants in the SUPREME-DM

StudyAnnual rate (per 100 person-years)2005–2011 weighted rateP value for time trendfP value across the groupsg
2005200620072008200920102011
Total person-years570,931594,929613,894629,894645,210662,035674,906
Overall
 Unadjusteda1.441.581.551.551.501.481.461.510.448
 Adjustedb1.471.591.511.491.361.371.471.470.011
Demographicsa
 Age (years)<0.001
  20–441.351.261.321.151.221.061.151.220.016
  45–540.961.030.990.991.020.930.930.980.357
  55–641.091.151.111.141.061.111.111.110.852
  65–741.581.811.761.711.631.601.521.660.034
  75–842.342.722.642.702.572.512.392.550.393
  ≥852.902.802.893.092.722.682.702.810.314
 Sex0.154
  Female1.471.611.601.601.541.511.411.530.173
  Male1.421.551.501.511.471.451.511.490.970
Comorbiditiesb
 CKD (cohort year)<0.001
  Yes7.166.204.955.775.044.484.515.26<0.001
  No0.961.050.980.940.970.850.880.950.083
 CHF (cohort year)<0.001
  Yes8.307.327.647.546.456.736.527.190.002
  No1.281.401.321.331.331.191.221.290.021
 CVD (cohort year)<0.001
  Yes6.695.466.395.725.034.594.185.37<0.001
  No1.031.151.041.041.070.950.971.030.190
 Depression (baseline)<0.001
  Yes2.252.242.382.122.131.762.032.120.041
  No1.391.491.401.441.391.291.281.380.003
Glycemic controlb
 A1C<0.001
  <7%1.001.201.060.920.860.920.790.96<0.001
  7–8%1.571.561.731.691.611.581.491.600.492
  8–9%2.201.912.232.462.352.171.892.170.748
  ≥9%2.442.532.542.602.772.482.692.580.442
Medication exposureb
 Diabetes medications<0.001
 Short-acting insulinc4.905.495.235.015.094.954.555.030.030
 Long-acting insulinc3.793.303.542.993.283.032.723.18<0.001
 Secretagoguesd0.970.880.910.970.870.881.010.930.764
 Other drugse0.420.390.420.410.440.420.390.410.999
 β-Blockers<0.001
  Yes2.462.472.383.292.992.041.652.460.173
  No1.361.451.381.361.351.231.251.340.417
  • aUnadjusted.

  • bAdjusted for age and sex. Categories are not mutually exclusive.

  • cShort-acting insulin category includes patients additionally on long-acting insulin or on premixed insulin. Long-acting insulin category also includes patients on combination or premixed insulin. Includes NPH insulin.

  • dInsulin secretagogues include sulfonylurea, combined sulfonylurea/biguanide, and meglitinides.

  • eOther drugs include metformin, thiazolidinediones, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, and GLP-1 agonists.

  • fTest for monotonic trend across the years within each group from 2005 to 2011.

  • gTest for whether average weighted rates differ between subgroups (e.g., female vs. male).